Nephrology Times
Nephrology Times
Advertisement
Sarah TolsonFrom the Field | May 8, 2025
Sarah Tolson reviews how changes to reimbursement for phosphate binders have affected dialysis programs.
Charlotte RobinsonAcute Kidney Injury | May 8, 2025
A study assessed whether proton pump inhibitor use accelerated CKD progression and acute kidney injury risk.
Pranav Garimella, MBBS, MPHNephrology Times | May 7, 2025
Dr. Pranav Garimella, CMO of the American Kidney Fund, discussed AMKD awareness and the importance of APOL1 gene variants.
Charlotte RobinsonAcute Kidney Injury | May 7, 2025
A study examined whether treatment of in-hospital BP elevations increases the risk of AKI and other adverse outcomes.
Charlotte RobinsonGout | May 6, 2025
Researchers assessed the potential association between serum uric acid levels and CV events after kidney transplantation.
Charlotte RobinsonGout | May 5, 2025
A study examined dosing practices and effectiveness of the urate-lowering drug allopurinol.
Charlotte RobinsonADPKD | May 2, 2025
Novartis will acquire Regulus Therapeutics, developer of ADPKD therapeutic candidate farabursen, a novel oligonucleotide.
Charlotte RobinsonNephrology Times | May 2, 2025
KDIGO has issued its first updated guideline on the management of nephrotic syndrome in children since 2021.
Mini Michael, MDNKF Spring Clinical Meetings 2025 | May 2, 2025
Joel Topf spoke with Mini Michael about the ILLUMINATE-B study of lumasiran for PH1 in infants and young children.
Charlotte RobinsonIgA Nephropathy | May 1, 2025
The European Commission has granted standard approval to sparsentan for the treatment of adults with primary IgA nephropathy.
Richard Lafayette, MDIgA Nephropathy | May 1, 2025
We spoke with ALIGN study investigator Richard Lafayette, MD, upon the FDA's accelerated approval of atrasentan for IgAN.
Melanie Betz, MS, RD, CSR, FNKF, FANDNKF Spring Clinical Meetings 2025 | May 1, 2025
Joel Topf spoke with dietitian Melanie Betz about potassium, oxalate, and other renal nutrition concerns.
Areef Ishani, MDNKF Spring Clinical Meetings 2025 | April 30, 2025
Joel Topf spoke with Areef Ishani about kidney stone outcomes from the Diuretic Comparison Project, a study of US veterans.
Roger Rodby, MDNKF Spring Clinical Meetings 2025 | April 29, 2025
Joel Topf spoke to Seldin Award winner Roger Rodby at the National Kidney Foundation Spring Clinical Meetings 2025.
Kathleen Liu, MDNKF Spring Clinical Meetings 2025 | April 28, 2025
Joel Topf spoke with Kathleen Liu about acute kidney injury and other topics ahead of her Massry lecture at SCM25.
Charlotte RobinsonADPKD | April 25, 2025
Lupin's generic tolvaptan tablets are now FDA-approved for treating autosomal dominant polycystic kidney disease (ADPKD).
Bradley Warady, MDNKF Spring Clinical Meetings 2025 | April 25, 2025
We spoke to David M. Hume Award winner Bradley Warady, MD, at the National Kidney Foundation Spring Clinical Meetings 2025.
Meghan Sise, MDNKF Spring Clinical Meetings 2025 | April 24, 2025
Joel Topf spoke to onconephrologist Meghan Sise about her carboplatin dosing research at SCM25.
James Tumlin, MDNKF Spring Clinical Meetings 2025 | April 23, 2025
Joel Topf caught up with James Tumlin at NKF SCM25 to talk about Dr. Tumlin's late-breaking abstract on sparsentan in FSGS.
Freely FilteredNephrology Times | April 22, 2025
This Freely Filtered episode discusses REGENCY, examining the efficacy and safety of obinutuzumab in active lupus nephritis.
Advertisement